Pre-order Enquiry
Request Free Sample
COVID-19 Impact on Rare Disease Drug Market, Global Research Reports 2020-2021
SKU ID : QYR-15719381 | Publishing Date : 28-May-2020 | No. of pages : 105
Detailed TOC of COVID-19 Impact on Rare Disease Drug Market, Global Research Reports 2020-2021
1.1 Research Scope1.2 Market Segmentation
1.3 Research Objectives
1.4 Research Methodology
1.4.1 Research Process
1.4.2 Data Triangulation
1.4.3 Research Approach
1.4.4 Base Year
1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.5.2 Covid-19 Impact: Commodity Prices Indices
1.5.3 Covid-19 Impact: Global Major Government Policy
1.6 The Covid-19 Impact on Rare Disease Drug Industry
1.7 COVID-19 Impact: Rare Disease Drug Market Trends
2 Global Rare Disease Drug Quarterly Market Size Analysis
2.1 Rare Disease Drug Business Impact Assessment - COVID-19
2.1.1 Global Rare Disease Drug Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
2.1.2 Global Rare Disease Drug Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
2.2 Global Rare Disease Drug Quarterly Market Size 2020-2021
2.3 COVID-19-Driven Market Dynamics and Factor Analysis
2.3.1 Drivers
2.3.2 Restraints
2.3.3 Opportunities
2.3.4 Challenges
3 Quarterly Competitive Assessment, 2020
3.1 Global Rare Disease Drug Quarterly Market Size by Manufacturers, 2019 VS 2020
3.2 Global Rare Disease Drug Factory Price by Manufacturers
3.3 Location of Key Manufacturers Rare Disease Drug Manufacturing Factories and Area Served
3.4 Date of Key Manufacturers Enter into Rare Disease Drug Market
3.5 Key Manufacturers Rare Disease Drug Product Offered
3.6 Mergers & Acquisitions, Expansion Plans
4 Impact of Covid-19 on Rare Disease Drug Segments, By Type
4.1 Introduction
1.4.1 Above 1‰
1.4.2 0.65‰～1‰
1.4.3 Below 0.1‰
4.2 By Type, Global Rare Disease Drug Market Size, 2019-2021
4.2.1 By Type, Global Rare Disease Drug Market Size by Type, 2020-2021
4.2.2 By Type, Global Rare Disease Drug Price, 2020-2021
5 Impact of Covid-19 on Rare Disease Drug Segments, By Application
5.1 Overview
5.5.1 Hospital Pharmacies
5.5.2 Speciality Pharmacies
5.5.3 Retail pharmacies
5.5.4 Others
5.2 By Application, Global Rare Disease Drug Market Size, 2019-2021
5.2.1 By Application, Global Rare Disease Drug Market Size by Application, 2019-2021
5.2.2 By Application, Global Rare Disease Drug Price, 2020-2021
6 Geographic Analysis
6.1 Introduction
6.2 North America
6.2.1 Macroeconomic Indicators of US
6.2.2 US
6.2.3 Canada
6.3 Europe
6.3.1 Macroeconomic Indicators of Europe
6.3.2 Germany
6.3.3 France
6.3.4 UK
6.3.5 Italy
6.4 Asia-Pacific
6.4.1 Macroeconomic Indicators of Asia-Pacific
6.4.2 China
6.4.3 Japan
6.4.4 South Korea
6.4.5 India
6.4.6 ASEAN
6.5 Rest of World
6.5.1 Latin America
6.5.2 Middle East and Africa
7 Company Profiles
7.1 Novartis AG
7.1.1 Novartis AG Business Overview
7.1.2 Novartis AG Rare Disease Drug Quarterly Production and Revenue, 2020
7.1.3 Novartis AG Rare Disease Drug Product Introduction
7.1.4 Novartis AG Response to COVID-19 and Related Developments
7.2 Bristol-Myers Squibb Company
7.2.1 Bristol-Myers Squibb Company Business Overview
7.2.2 Bristol-Myers Squibb Company Rare Disease Drug Quarterly Production and Revenue, 2020
7.2.3 Bristol-Myers Squibb Company Rare Disease Drug Product Introduction
7.2.4 Bristol-Myers Squibb Company Response to COVID-19 and Related Developments
7.3 Celgene Corporation
7.3.1 Celgene Corporation Business Overview
7.3.2 Celgene Corporation Rare Disease Drug Quarterly Production and Revenue, 2020
7.3.3 Celgene Corporation Rare Disease Drug Product Introduction
7.3.4 Celgene Corporation Response to COVID-19 and Related Developments
7.4 F. Hoffmann-La Roche Ltd.
7.4.1 F. Hoffmann-La Roche Ltd. Business Overview
7.4.2 F. Hoffmann-La Roche Ltd. Rare Disease Drug Quarterly Production and Revenue, 2020
7.4.3 F. Hoffmann-La Roche Ltd. Rare Disease Drug Product Introduction
7.4.4 F. Hoffmann-La Roche Ltd. Response to COVID-19 and Related Developments
7.5 Pfizer, Inc.
7.5.1 Pfizer, Inc. Business Overview
7.5.2 Pfizer, Inc. Rare Disease Drug Quarterly Production and Revenue, 2020
7.5.3 Pfizer, Inc. Rare Disease Drug Product Introduction
7.5.4 Pfizer, Inc. Response to COVID-19 and Related Developments
7.6 Sanofi S.A.
7.6.1 Sanofi S.A. Business Overview
7.6.2 Sanofi S.A. Rare Disease Drug Quarterly Production and Revenue, 2020
7.6.3 Sanofi S.A. Rare Disease Drug Product Introduction
7.6.4 Sanofi S.A. Response to COVID-19 and Related Developments
7.7 Alexion Pharmaceuticals, Inc.
7.7.1 Alexion Pharmaceuticals, Inc. Business Overview
7.7.2 Alexion Pharmaceuticals, Inc. Rare Disease Drug Quarterly Production and Revenue, 2020
7.7.3 Alexion Pharmaceuticals, Inc. Rare Disease Drug Product Introduction
7.7.4 Alexion Pharmaceuticals, Inc. Response to COVID-19 and Related Developments
7.8 Eli Lilly and Company
7.8.1 Eli Lilly and Company Business Overview
7.8.2 Eli Lilly and Company Rare Disease Drug Quarterly Production and Revenue, 2020
7.8.3 Eli Lilly and Company Rare Disease Drug Product Introduction
7.8.4 Eli Lilly and Company Response to COVID-19 and Related Developments
7.9 Novo Nordisk A/S
7.9.1 Novo Nordisk A/S Business Overview
7.9.2 Novo Nordisk A/S Rare Disease Drug Quarterly Production and Revenue, 2020
7.9.3 Novo Nordisk A/S Rare Disease Drug Product Introduction
7.9.4 Novo Nordisk A/S Response to COVID-19 and Related Developments
7.10 AstraZeneca
7.10.1 AstraZeneca Business Overview
7.10.2 AstraZeneca Rare Disease Drug Quarterly Production and Revenue, 2020
7.10.3 AstraZeneca Rare Disease Drug Product Introduction
7.10.4 AstraZeneca Response to COVID-19 and Related Developments
7.11 Eisai Co., Ltd.
7.11.1 Eisai Co., Ltd. Business Overview
7.11.2 Eisai Co., Ltd. Rare Disease Drug Quarterly Production and Revenue, 2020
7.11.3 Eisai Co., Ltd. Rare Disease Drug Product Introduction
7.11.4 Eisai Co., Ltd. Response to COVID-19 and Related Developments
7.12 Daiichi Sankyo Company Limited
7.12.1 Daiichi Sankyo Company Limited Business Overview
7.12.2 Daiichi Sankyo Company Limited Rare Disease Drug Quarterly Production and Revenue, 2020
7.12.3 Daiichi Sankyo Company Limited Rare Disease Drug Product Introduction
7.12.4 Daiichi Sankyo Company Limited Response to COVID-19 and Related Developments
7.13 Bayer AG
7.13.1 Bayer AG Business Overview
7.13.2 Bayer AG Rare Disease Drug Quarterly Production and Revenue, 2020
7.13.3 Bayer AG Rare Disease Drug Product Introduction
7.13.4 Bayer AG Response to COVID-19 and Related Developments
7.14 GlaxoSmithKline
7.14.1 GlaxoSmithKline Business Overview
7.14.2 GlaxoSmithKline Rare Disease Drug Quarterly Production and Revenue, 2020
7.14.3 GlaxoSmithKline Rare Disease Drug Product Introduction
7.14.4 GlaxoSmithKline Response to COVID-19 and Related Developments
7.15 Merck & Co., Inc.
7.15.1 Merck & Co., Inc. Business Overview
7.15.2 Merck & Co., Inc. Rare Disease Drug Quarterly Production and Revenue, 2020
7.15.3 Merck & Co., Inc. Rare Disease Drug Product Introduction
7.15.4 Merck & Co., Inc. Response to COVID-19 and Related Developments
7.16 Johnson & Johnson
7.16.1 Johnson & Johnson Business Overview
7.16.2 Johnson & Johnson Rare Disease Drug Quarterly Production and Revenue, 2020
7.16.3 Johnson & Johnson Rare Disease Drug Product Introduction
7.16.4 Johnson & Johnson Response to COVID-19 and Related Developments
7.17 Biogen, Inc.
7.17.1 Biogen, Inc. Business Overview
7.17.2 Biogen, Inc. Rare Disease Drug Quarterly Production and Revenue, 2020
7.17.3 Biogen, Inc. Rare Disease Drug Product Introduction
7.17.4 Biogen, Inc. Response to COVID-19 and Related Developments
7.18 Takeda
7.18.1 Takeda Business Overview
7.18.2 Takeda Rare Disease Drug Quarterly Production and Revenue, 2020
7.18.3 Takeda Rare Disease Drug Product Introduction
7.18.4 Takeda Response to COVID-19 and Related Developments
7.19 Amgen, Inc.
7.19.1 Amgen, Inc. Business Overview
7.19.2 Amgen, Inc. Rare Disease Drug Quarterly Production and Revenue, 2020
7.19.3 Amgen, Inc. Rare Disease Drug Product Introduction
7.19.4 Amgen, Inc. Response to COVID-19 and Related Developments
7.20 Deciphera
7.20.1 Deciphera Business Overview
7.20.2 Deciphera Rare Disease Drug Quarterly Production and Revenue, 2020
7.20.3 Deciphera Rare Disease Drug Product Introduction
7.20.4 Deciphera Response to COVID-19 and Related Developments
7.21 Atara Biotherapeutics
7.21.1 Atara Biotherapeutics Business Overview
7.21.2 Atara Biotherapeutics Rare Disease Drug Quarterly Production and Revenue, 2020
7.21.3 Atara Biotherapeutics Rare Disease Drug Product Introduction
7.21.4 Atara Biotherapeutics Response to COVID-19 and Related Developments
7.22 ProQR
7.22.1 ProQR Business Overview
7.22.2 ProQR Rare Disease Drug Quarterly Production and Revenue, 2020
7.22.3 ProQR Rare Disease Drug Product Introduction
7.22.4 ProQR Response to COVID-19 and Related Developments
8 Supply Chain and Sales Channels Analysis
8.1 Rare Disease Drug Supply Chain Analysis
8.1.1 Rare Disease Drug Supply Chain Analysis
8.1.2 Covid-19 Impact on Rare Disease Drug Supply Chain
8.2 Distribution Channels Analysis
8.2.1 Rare Disease Drug Distribution Channels
8.2.2 Covid-19 Impact on Rare Disease Drug Distribution Channels
8.2.3 Rare Disease Drug Distributors
8.3 Rare Disease Drug Customers
9 Key Findings
10 Appendix
10.1 About Us
10.2 Disclaimer
List of Figures, Tables and Charts Available in COVID-19 Impact on Rare Disease Drug Market, Global Research Reports 2020-2021
List of TablesTable 1. Overview of the World Economic Outlook Projections
Table 2. Summary of World Real per Capita Output (Annual percent change; in international currency at purchasing power parity)
Table 3. European Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 4. Asian and Pacific Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 5. Western Hemisphere Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 6. Middle Eastern and Central Asian Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 7. Covid-19 Impact: Global Major Government Policy
Table 8. The Covid-19 Impact on Rare Disease Drug Assessment
Table 9. COVID-19 Impact: Rare Disease Drug Market Trends
Table 10. COVID-19 Impact Global Rare Disease Drug Market Size
Table 11. Global Rare Disease Drug Market Size Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 (K Doses)
Table 12. Global Rare Disease Drug Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026, (USD/Dose)
Table 13. Global Rare Disease Drug Quarterly Market Size, 2020 (US$ Million) & (K Doses)
Table 14. Global Rare Disease Drug Market Size, Pre-COVID-19 and Post- COVID-19 Quarterly Comparison, 2020-2021 (US$ Million)
Table 15. Global Rare Disease Drug Market Size, Pre-COVID-19 and Post- COVID-19 Quarterly Comparison, 2020-2021 (K Doses)
Table 16. Global Rare Disease Drug Market Growth Drivers
Table 17. Global Rare Disease Drug Market Restraints
Table 18. Global Rare Disease Drug Market Opportunities
Table 19. Global Rare Disease Drug Market Challenges
Table 20. Key Manufacturers Rare Disease Drug Quarterly Revenue, 2019 VS 2020 (US$ Million)
Table 21. Top Manufacturers, Rare Disease Drug Market Size, 2019 (K Doses) & (US$ Million)
Table 22. Rare Disease Drug Factory Price by Manufacturers 2020 (USD/Dose)
Table 23. Location of Key Manufacturers Rare Disease Drug Manufacturing Plants
Table 24. Key Manufacturers Rare Disease Drug Market Served
Table 25. Date of Key Manufacturers Enter into Rare Disease Drug Market
Table 26. Key Manufacturers Rare Disease Drug Product Type
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Rare Disease Drug Market Size by Type, 2020, (US$ Million)
Table 29. Global Rare Disease Drug Market Size by Type, 2020 (K Doses)
Table 30. Global Rare Disease Drug Price: by Type, 2020-2021 (USD/Dose)
Table 31. Global Rare Disease Drug Market Size by Application: 2020-2021 (US$ Million)
Table 32. Global Rare Disease Drug Market Size by Application, 2020-2021 (K Doses)
Table 33. Global Rare Disease Drug Price: by Application, 2020-2021 (USD/Dose)
Table 34. Global Rare Disease Drug Market Size by Region, 2019-2021 (US$ Million)
Table 35. Global Rare Disease Drug Market Size by Region, 2019-2021 (K Doses)
Table 36. By Country, North America Rare Disease Drug Market Size, 2019-2021 (US$ Million)
Table 37. By Country, North America Rare Disease Drug Market Size, 2019-2021 (K Doses)
Table 38. US Rare Disease Drug Market Size, 2019-2021 (US$ Million) & (K Doses)
Table 39. Canada Rare Disease Drug Market Size, 2019-2021 (US$ Million) & (K Doses)
Table 40. Macroeconomic Indicators of Europe (Germany, France, UK and Italy)
Table 41. By Country, Europe Rare Disease Drug Market Size, 2019-2021 (US$ Million)
Table 42. By Country, Europe Rare Disease Drug Market Size, 2019-2021 (K Doses)
Table 43. Germany Rare Disease Drug Market Size, 2019-2021 (US$ Million) & (K Doses)
Table 44. France Rare Disease Drug Market Size, 2019-2021 (US$ Million) & (K Doses)
Table 45. UK Rare Disease Drug Market Size, 2019-2021 (US$ Million) & (K Doses)
Table 46. Italy Rare Disease Drug Market Size, 2019-2021 (US$ Million) & (K Doses)
Table 47. Macroeconomic Indicators of Asia-Pacific (China, Japan, South Korea, India and ASEAN)
Table 48. By Region, Asia-Pacific Rare Disease Drug Market Size, 2019-2021 (US$ Million)
Table 49. By Region, Asia-Pacific Rare Disease Drug Market Size, 2019-2021 (K Doses)
Table 50. China Rare Disease Drug Market Size, 2019-2021 (US$ Million) & (K Doses)
Table 51. Japan Rare Disease Drug Market Size, 2019-2021 (US$ Million) & (K Doses)
Table 52. South Korea Rare Disease Drug Market Size, 2019-2021 (US$ Million) & (K Doses)
Table 53. India Rare Disease Drug Market Size, 2019-2021 (US$ Million) & (K Doses)
Table 54. ASEAN Rare Disease Drug Market Size, 2019-2021 (US$ Million) & (K Doses)
Table 55. Latin America Rare Disease Drug Market Size, 2019-2021 (US$ Million) & (K Doses)
Table 56. Middle East and Africa Rare Disease Drug Market Size, 2019-2021 (US$ Million) & (K Doses)
Table 57. Novartis AG Business Overview
Table 58. Novartis AG Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 59. Novartis AG Rare Disease Drug Product
Table 60. Novartis AG Response to COVID-19 and Related Developments
Table 61. Bristol-Myers Squibb Company Business Overview
Table 62. Bristol-Myers Squibb Company Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 63. Bristol-Myers Squibb Company Rare Disease Drug Product
Table 64. Bristol-Myers Squibb Company Response to COVID-19 and Related Developments
Table 65. Celgene Corporation Business Overview
Table 66. Celgene Corporation Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 67. Celgene Corporation Rare Disease Drug Product
Table 68. Celgene Corporation Response to COVID-19 and Related Developments
Table 69. F. Hoffmann-La Roche Ltd. Business Overview
Table 70. F. Hoffmann-La Roche Ltd. Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 71. F. Hoffmann-La Roche Ltd. Rare Disease Drug Product
Table 72. F. Hoffmann-La Roche Ltd. Response to COVID-19 and Related Developments
Table 73. Pfizer, Inc. Business Overview
Table 74. Pfizer, Inc. Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 75. Pfizer, Inc. Rare Disease Drug Product
Table 76. Pfizer, Inc. Response to COVID-19 and Related Developments
Table 77. Sanofi S.A. Business Overview
Table 78. Sanofi S.A. Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 79. Sanofi S.A. Rare Disease Drug Product
Table 80. Sanofi S.A. Response to COVID-19 and Related Developments
Table 81. Alexion Pharmaceuticals, Inc. Business Overview
Table 82. Alexion Pharmaceuticals, Inc. Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 83. Alexion Pharmaceuticals, Inc. Rare Disease Drug Product
Table 84. Alexion Pharmaceuticals, Inc. Response to COVID-19 and Related Developments
Table 85. Eli Lilly and Company Business Overview
Table 86. Eli Lilly and Company Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 87. Eli Lilly and Company Rare Disease Drug Product
Table 88. Eli Lilly and Company Response to COVID-19 and Related Developments
Table 89. Novo Nordisk A/S Business Overview
Table 90. Novo Nordisk A/S Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 91. Novo Nordisk A/S Rare Disease Drug Product
Table 92. Novo Nordisk A/S Response to COVID-19 and Related Developments
Table 93. AstraZeneca Business Overview
Table 94. AstraZeneca Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 95. AstraZeneca Rare Disease Drug Product
Table 96. AstraZeneca Response to COVID-19 and Related Developments
Table 97. Eisai Co., Ltd. Business Overview
Table 98. Eisai Co., Ltd. Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 99. Eisai Co., Ltd. Rare Disease Drug Product
Table 100. Eisai Co., Ltd. Response to COVID-19 and Related Developments
Table 101. Daiichi Sankyo Company Limited Business Overview
Table 102. Daiichi Sankyo Company Limited Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 103. Daiichi Sankyo Company Limited Rare Disease Drug Product
Table 104. Daiichi Sankyo Company Limited Response to COVID-19 and Related Developments
Table 105. Bayer AG Business Overview
Table 106. Bayer AG Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 107. Bayer AG Rare Disease Drug Product
Table 108. Bayer AG Response to COVID-19 and Related Developments
Table 109. GlaxoSmithKline Business Overview
Table 110. GlaxoSmithKline Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 111. GlaxoSmithKline Rare Disease Drug Product
Table 112. GlaxoSmithKline Response to COVID-19 and Related Developments
Table 113. Merck & Co., Inc. Business Overview
Table 114. Merck & Co., Inc. Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 115. Merck & Co., Inc. Rare Disease Drug Product
Table 116. Merck & Co., Inc. Response to COVID-19 and Related Developments
Table 117. Johnson & Johnson Business Overview
Table 118. Johnson & Johnson Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 119. Johnson & Johnson Rare Disease Drug Product
Table 120. Johnson & Johnson Response to COVID-19 and Related Developments
Table 121. Biogen, Inc. Business Overview
Table 122. Biogen, Inc. Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 123. Biogen, Inc. Rare Disease Drug Product
Table 124. Biogen, Inc. Response to COVID-19 and Related Developments
Table 125. Takeda Business Overview
Table 126. Takeda Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 127. Takeda Rare Disease Drug Product
Table 128. Takeda Response to COVID-19 and Related Developments
Table 129. Amgen, Inc. Business Overview
Table 130. Amgen, Inc. Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 131. Amgen, Inc. Rare Disease Drug Product
Table 132. Amgen, Inc. Response to COVID-19 and Related Developments
Table 133. Deciphera Business Overview
Table 134. Deciphera Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 135. Deciphera Rare Disease Drug Product
Table 136. Deciphera Response to COVID-19 and Related Developments
Table 137. Atara Biotherapeutics Business Overview
Table 138. Atara Biotherapeutics Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 139. Atara Biotherapeutics Rare Disease Drug Product
Table 140. Atara Biotherapeutics Response to COVID-19 and Related Developments
Table 141. ProQR Business Overview
Table 142. ProQR Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 143. ProQR Rare Disease Drug Product
Table 144. ProQR Response to COVID-19 and Related Developments
Table 145. Rare Disease Drug Distributors List
Table 146. Rare Disease Drug Customers List
Table 147. Covid-19 Impact on Rare Disease Drug Customers
List of Figures
Figure 1. Rare Disease Drug Product Picture
Figure 2. Rare Disease Drug Market Segmentation
Figure 3. Research Objectives
Figure 4. Research Process
Figure 5. Data Triangulation
Figure 6. Research Approach
Figure 7. Commodity Prices-Metals Price Indices
Figure 8. Commodity Prices- Precious Metal Price Indices
Figure 9. Commodity Prices- Agricultural Raw Material Price Indices
Figure 10. Commodity Prices- Food and Beverage Price Indices
Figure 11. Commodity Prices- Fertilizer Price Indices
Figure 12. Commodity Prices- Energy Price Indices
Figure 13. G20+: Economic Policy Responses to COVID-19
Figure 14. Global Rare Disease Drug Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 (US$ Million)
Figure 15. Global Rare Disease Drug Market Size, Pre-COVID-19 and Post- COVID-19, Year-over-Year Growth Rate, 2015-2026 (%)
Figure 16. Global Rare Disease Drug Market Size, Quarterly Growth, 2020-2021 (%)
Figure 17. Global Rare Disease Drug Market Size, Market Share by Type, 2019 VS 2020 (%)
Figure 18. Global Rare Disease Drug Market Size, Market Share by Application, 2019 VS 2020 (%)
Figure 19. Global Rare Disease Drug Market Size Market Share by Region, 2019 VS 2020 (%)
Figure 20. United States Composite PMI and GDP
Figure 21. Eurozone Composite PMI and GDP
Figure 22. Eurozone Core v. Periphery PMI Output Indices
Figure 23. Core v. Periphery PMI Employment Indices
Figure 24. UK Composite PMI and GDP
Figure 25. Caixin China Composite Output Index
Figure 26. Caixin China General Services Business Activity Index
Figure 27. Japan Composite Output Index
Figure 28. South Korea Manufacturing PMI
Figure 29. India Composite Output Index
Figure 30. ASEAN Manufacturing PMI
Figure 31. By Region, Asia-Pacific Rare Disease Drug Market Size Market Share, 2019-2021
Keyplayers in COVID-19 Impact on Rare Disease Drug Market, Global Research Reports 2020-2021
Novartis AGBristol-Myers Squibb Company
Celgene Corporation
F. Hoffmann-La Roche Ltd.
Pfizer, Inc.
Sanofi S.A.
Alexion Pharmaceuticals, Inc.
Eli Lilly and Company
Novo Nordisk A/S
AstraZeneca
Eisai Co., Ltd.
Daiichi Sankyo Company Limited
Bayer AG
GlaxoSmithKline
Merck & Co., Inc.
Johnson & Johnson
Biogen, Inc.
Takeda
Amgen, Inc.
Deciphera
Atara Biotherapeutics
ProQR
Request Sample
Request Discount
